Abstract: A method for performing magnetic resonance imaging on a subject comprises obtaining undersampled imaging data, extracting one or more temporal basis functions from the imaging data, extracting one or more preliminary spatial weighting functions from the imaging data, inputting the one or more preliminary spatial weighting functions into a neural network to produce one or more final spatial weighting functions, and multiplying the one or more final spatial weighting functions by the one or more temporal basis functions to generate an image sequence. Each of the temporal basis functions corresponds to at least one time-varying dimension of the subject. Each of the preliminary spatial weighting functions corresponds to a spatially-varying dimension of the subject. Each of the final spatial weighting functions is an artifact-free estimation of the one of the one or more preliminary spatial weighting functions.

Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Abstract: An antenna unit, a radio unit, and a base station are disclosed. The antenna unit or the radio unit includes a plurality of filters, each having a respective radio frequency passband. At least one first filter is a CWG filter. The first filter is coupled to a second filter through a T-junction formed on an antenna board or a radio mother board.

Abstract: A method and system for treating a hormonal disorder comprising injecting a composition comprising an effective amount of leuprolide or a salt thereof to a patient suffering from the hormonal disorder, with the system comprising N-methylpyrrolidone (NMP) and a polymer having a weight average molecular weight between 5,000 and 50,000 Dalton, an acid number of less than 3 mgKOH/g.

Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a strong acid salt and a weak acid of a LHRH agonist or antagonist; b) a biodegradable polymer of poly(lactide-co-glycolide), wherein the ratio of lactide:glycolide of the copolymer is from 50:50 to about 100:0; and c) N-methyl-2-pyrrolidone (NMP), wherein the composition does not contain excess strong acid in addition to the strong acid used to form the salt of the LHRH agonist or antagonist. The composition, when injected, can provide a controlled release of leuprolide for a period of up to 6 months.

Abstract: The present application provides a method for the manufacture of a viscous liquid suspension or emulsion for controlled release drug delivery, where the composition comprises: a lactate-based polymer having a weight average molecular weight between 5,000 and 50,000 dalton; a biocompatible solvent; and a bioactive substance or a salt thereof. The method involves weighing, mixing, dissolving the raw materials, filtering the product, and degassing the product to produce a uniform formulation that can be accurately filled in a single ready to use syringe.

Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a strong acid salt and a weak acid of a LHRH agonist or antagonist; b) a biodegradable polymer of poly(lactide-co-glycolide), wherein the ratio of lactide:glycolide of the copolymer is from 50:50 to about 100:0; and c) N-methyl-2-pyrrolidone (NMP), wherein the composition does not contain excess strong acid in addition to the strong acid used to form the salt of the LHRH agonist or antagonist. The composition, when injected, can provide a controlled release of leuprolide for a period of up to 6 months.

Abstract: Methods of safely administrating a matrix metalloproteinase 12 (MMP-12) inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis, by oral administration of an MMP-12 inhibitor.

Abstract: Methods of treating acute respiratory distress syndrome (ARDS) by administration of a matrix metalloproteinase (MMP) inhibitor are described.

Abstract: The present invention provides a depot composition suitable to deliver a VMAT2 inhibitor in a controlled manner. The composition of the present invention comprises: (a) a VMAT2 inhibitor and (b) a pharmaceutically acceptable oil. Optionally, the depot composition of the present invention also comprises an excipient to achieve optimal delivery of the VMAT2 inhibitor. The present invention also provides a method for making such depot composition.

Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a strong acid salt and a weak acid of a LHRH agonist or antagonist; b) a biodegradable polymer of poly(lactide-co-glycolide), wherein the ratio of lactide:glycolide of the copolymer is from 50:50 to about 100:0; and c) N-methyl-2-pyrrolidone (NMP), wherein the composition does not contain excess strong acid in addition to the strong acid used to form the salt of the LHRH agonist or antagonist. The composition, when injected, can provide a controlled release of leuprolide for a period of up to 6 months.

Abstract: The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.

Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a strong acid salt of a LHRH agonist or antagonist; b) a biodegradable polymer of poly(lactide-co-glycolide), wherein the ratio of lactide:glycolide of the copolymer is from 50:50 to about 100:0; and c) N-methyl-2-pyrrolidone (NMP), wherein the composition does not contain excess strong acid in addition to the strong acid used to form the salt of the LHRH agonist or antagonist. The composition, when injected, can provide a controlled release of leuprolide for a period of up to 6 months.

Abstract: A mobile DR applicable to in-vivo detection of multi-thoracolumbar variations in equine animals and a use method are provided. The DR mainly comprises four aspects: (1) a digital flat-panel X-ray imaging system; (2) equine animal retaining device system (radiography bed) applicable to different body sizes; (3) radiography parameters applicable to equine animals of different body sizes and at different developmental stages; and (4) a stitching system Polaris for radiographed pictures. The digital flat-panel X-ray imaging system comprises an X-ray tube, a beam limiting device, a high-voltage generator, a flat-panel detector, an image acquisition workstation.

Abstract: The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.

Abstract: The present application relates to a sustained release delivery composition of a vesicular monoamine transporter type 2 (VMAT2) inhibitor, a deuterated derivative thereof, a pharmaceutically acceptable salt thereof, an active metabolite thereof, or a prodrug thereof for treatment of hyperkinetic movement disorders including, but not limited to, tardive dyskinesia (TD), Huntington's disease (HD) chorea, tremors, dystonia, chorea, tics, myoclonus, stereotypies, restless legs syndrome, and various other disorders with abnormal involuntary movements. The method of making or using the composition is also disclosed.

Abstract: The present invention is directed to a depot composition for sustained release delivery of buprenorphine with enhanced stability and bioavailability. The composition is an injectable, low viscosity liquid and can form a depot in situ capable of delivering therapeutic level of buprenorphine over a period of time from one week to 3 months.

Abstract: The present invention provides an injectable composition for controlled release drug delivery and the process of making the same, where the composition comprises: a lactate-based polymer having a weight average molecular weight between 5,000 and 50,000 dalton, an acid number of less than 3 mgKOH/g and the content of residual lactide monomers in the lactate-based polymer of less than about 0.3% by weight; a pharmaceutically acceptable organic solvent; and a bioactive substance or a salt thereof that contains an amino acid serine in the molecular structure that is capable of reacting with lactide monomer to form a conjugate; and where the composition reduces the formation of the conjugate.

Abstract: The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof. wherein R1 is —C(?O)O-alkyl, carbonate ester, or —C(?O)-alkyl, ester, or —C(?O)N-alkyl, carbamate ester and wherein R2 is —CH3 or —CD3. The alkyl ester can contain saturated or unsaturated C12 to C26 alkyl carbon. The alkyl carbon chain can have either a straight, branched, noncyclic, cyclic, unsubstituted or substituted structure.

Abstract: The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.